GENEVA—Reviews of CD8-positive T-cell infiltration as an independent prognostic biomarker in resected non-small cell lung cancer, and the potential of checkpoint inhibitor therapy for mesothelioma aft
GENEVA—Reviews of CD8-positive T-cell infiltration as an independent prognostic biomarker in resected non-small cell lung cancer, and the potential of checkpoint inhibitor therapy for mesothelioma after first or second line chemotherapy were presented at the European Lung Cancer Conference by Martin Reck MD PhD, from the Lung Clinic Grosshansdorf in Germany. He discussed the clinical implications with Oncology Times reporter Peter Goodwin.